Ki 8751

Cat. No. 2542 3 篇引用文献提交评论说明书 / 分析证书（CoA） / 化学品安全技术说明书（SDS）

Pricing	Availability		Qty

说明： Potent, selective VEGFR-2 inhibitor

化学名： N-(2,4-Difluorophenyl)-N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-fluorophenyl]urea

纯度： ≥97% (HPLC)

引用文献 (3)

文献 (1)

通路 (1)

生物活性技术数据溶解性计算器说明书参考文献

生物活性 for Ki 8751

Ki 8751 is a potent, selective inhibitor of VEGFR-2 tyrosine kinase (IC₅₀ = 0.9 nM). Displays some inhibitory activity towards c-Kit, PDGFRα and FGFR-2 (IC₅₀ values range from 40 to 170 nM) but is highly selective over other receptor tyrosine kinases (IC₅₀ > 10000 nM for FGFR-2, EGFR and HGFR). Inhibits VEGF-stimulated proliferation of human umbilical vein endothelial cells (HUVEC) and inhibits tumor growth in vivo; antiangiogenic.

化合物库 for Ki 8751

Ki 8751 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Kinase Inhibitor Library. 了解 Tocris 化合物库的更多信息。

技术数据 for Ki 8751

分子量	469.41
公式	C₂₄H₁₈F₃N₃O₄
储存	Store at +4°C
纯度	≥97% (HPLC)
CAS Number	228559-41-9
PubChem ID	11317348
InChI Key	LFKQSJNCVRGFCC-UHFFFAOYSA-N
Smiles	COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=CC=C(F)C=C4F)C(F)=C3)=CC=NC2=C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for Ki 8751

	溶剂	最高浓度 mg/mL	最高浓度 mM
溶解性
溶解性	DMSO	46.94	100

制备储备液 for Ki 8751

以下数据基于产品分子量 469.41。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

浓度/溶剂体积/质量	1 mg	5 mg	10 mg
1 mM	2.13 mL	10.65 mL	21.3 mL
5 mM	0.43 mL	2.13 mL	4.26 mL
10 mM	0.21 mL	1.07 mL	2.13 mL
50 mM	0.04 mL	0.21 mL	0.43 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

产品说明书 for Ki 8751

分析证书/产品说明书

化学品安全技术说明书

参考文献 for Ki 8751

参考文献是支持产品生物活性的出版物。

Kubo et al (2005) Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumour activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J.Med.Chem. 48 1359 PMID: 15743179

If you know of a relevant reference for Ki 8751, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 VEGFR Inhibitors

关键词: Ki 8751, Ki 8751 supplier, Potent, selective, VEGFR-2, inhibitors, inhibits, Vascular, Endothelial, Growth, Factors, Receptors, KDR, Flt, Receptor, Tyrosine, Kinases, RTKs, Ki8751, VEGFR, 2542, Tocris Bioscience

3 篇 Ki 8751 的引用文献

引用文献是使用了 Tocris 产品的出版物。 Ki 8751 的部分引用包括：

Marino et al (2018) Regulation of breast cancer induced bone disease by cancer-specific IKKβ. Oncotarget 9 16134 PMID: 29662632

Kawakami et al (2011) Investigation of a novel molecular descriptor for the lead optimization of 4-aminoquinazolines as vascular endothelial growth factor receptor-2 inhibitors: application for quantitative structure-activity relationship analysis in lead optimization. J Neurosci 21 1371 PMID: 21306896

Page et al (2019) Positive Feedback Defines the Timing, Magnitude, and Robustness of Angiogenesis. Cell Rep 27 3139 PMID: 31189101

您是否知道使用了 Tocris Ki 8751 的优秀论文？请告知我们.

Ki 8751 的评论

目前没有该产品的评论。 Be the first to review Ki 8751 and earn rewards!

Have you used Ki 8751?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。

Angiogenesis in Cancer Poster

This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.

Pathways for Ki 8751

VEGF Signaling Pathway

VEGF signaling pathway is involved in embryonic vascular development (vasculogenesis) and in the formation of new blood vessel (angiogenesis). It also induces cell migration, proliferation and survival.